The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.
Asymmetric catalytic intramolecular hydroacylation of 4-substituted pent-4-enals to β-substituted cyclopentanones
作者:Richard W. Barnhart、David A. McMorran、B. Bosnich
DOI:10.1039/a700076f
日期:——
The catalyst,
[Rh(S,S-Me-duphos)(acetone)
2
]
+
, rapidly and
efficiently converts 4-substituted pent-4-enals bearing primary and
secondary substituents to the corresponding cyclopentanones and for a
variety of substituents the ee was found to range from 93 to 96% at 25
°C.
GREENE, A. E.;CARBONNIER, F., TETRAHEDRON LETT., 1985, 26, N 45, 5525-5528
作者:GREENE, A. E.、CARBONNIER, F.
DOI:——
日期:——
METHOD FOR PREPARING TREPROSTINIL AND INTERMEDIATE THEREFOR
申请人:Yonsung Fine Chemical Co., Ltd.
公开号:EP3450421B1
公开(公告)日:2020-11-18
Asymmetric induction in the cycloaddition reaction of dichloroketene with chiral enol ethers. A versatile approach to optically active cyclopentenone derivatives.
作者:Andrew E. Greene、Florence Charbonnier
DOI:10.1016/s0040-4039(01)80878-9
日期:1985.1
Significant asymmetricinduction has been observed in the cycloaddition reaction of dichloroketene with chiral enol ethers. The resultant diastereomeric cyclobutanones have been converted to synthetically useful α-chlorocyclopentenones in optically active form.